3 Stocks Possibly Trading At A Discount Of Up To 37.8%

In the current U.S. market landscape, major stock indexes have recently experienced fluctuations, with notable gains following Nvidia's impressive earnings results and Walmart's strong performance. Amidst these developments, investors may find opportunities in stocks that are potentially trading below their intrinsic value, offering a chance to capitalize on market inefficiencies and economic shifts.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name	Current Price	Fair Value (Est)	Discount (Est)
TowneBank (TOWN)	$32.29	$62.85	48.6%
Perfect (PERF)	$1.74	$3.45	49.6%
Northwest Bancshares (NWBI)	$11.34	$22.10	48.7%
Horizon Bancorp (HBNC)	$15.74	$30.81	48.9%
Hasbro (HAS)	$76.47	$150.20	49.1%
Crocs (CROX)	$79.17	$155.89	49.2%
Caris Life Sciences (CAI)	$23.90	$46.82	49%
BILL Holdings (BILL)	$48.52	$94.27	48.5%
Beacon Financial (BBT)	$24.64	$48.61	49.3%
BCB Bancorp (BCBP)	$7.53	$14.72	48.8%

Click here to see the full list of 207 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's dive into some prime choices out of the screener.

NeuroPace (NPCE)

Overview: NeuroPace, Inc. is a medical device company in the United States with a market cap of $433.67 million.

Operations: The company's revenue is primarily derived from its Medical Products segment, totaling $94.86 million.

Estimated Discount To Fair Value: 17.7%

NeuroPace's recent earnings report shows a narrowing net loss, with third-quarter sales increasing to US$27.35 million from US$21.06 million year-over-year. The company has raised its full-year revenue guidance to between US$97 million and US$98 million, reflecting growth expectations of 21% to 23%. Despite trading at approximately 17.7% below its estimated fair value of US$17.13, NeuroPace remains highly volatile but is forecasted for strong profit growth over the next three years.

• According our earnings growth report, there's an indication that NeuroPace might be ready to expand.
• Get an in-depth perspective on NeuroPace's balance sheet by reading our health report here.

STAAR Surgical (STAA)

Overview: STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems, with a market cap of approximately $1.28 billion.

Operations: The company generates revenue from its ophthalmic surgical products, totaling $230.59 million.

Estimated Discount To Fair Value: 27.4%

STAAR Surgical's stock is trading at US$26.45, significantly below its estimated fair value of US$36.42, suggesting potential undervaluation based on cash flows. Despite forecasted revenue growth of 13.3% annually, which outpaces the broader U.S. market, the company faces significant shareholder opposition to its proposed sale to Alcon for US$28 per share amid concerns over valuation and strategic direction. The dissent among board members and activist investors highlights ongoing governance challenges that may impact future financial strategies and investor confidence.

• Our growth report here indicates STAAR Surgical may be poised for an improving outlook.
• Click here and access our complete balance sheet health report to understand the dynamics of STAAR Surgical.

Metropolitan Bank Holding (MCB)

Overview: Metropolitan Bank Holding Corp. is the bank holding company for Metropolitan Commercial Bank, offering a variety of business, commercial, and retail banking products and services with a market cap of $708.19 million.

Operations: Metropolitan Commercial Bank generates its revenue primarily from its banking segment, totaling $261.46 million.

Estimated Discount To Fair Value: 37.8%

Metropolitan Bank Holding is trading at US$69.65, notably below its estimated fair value of US$112.01, indicating potential undervaluation based on cash flows. Despite a recent dip in net income to US$7.12 million for Q3 2025 from US$12.27 million the previous year, revenue growth is projected at 14.7% annually, surpassing the U.S. market's average rate and supporting a strong earnings growth forecast of 26.8% per year over the next three years.

• In light of our recent growth report, it seems possible that Metropolitan Bank Holding's financial performance will exceed current levels.
• Take a closer look at Metropolitan Bank Holding's balance sheet health here in our report.

Next Steps

• Unlock our comprehensive list of 207 Undervalued US Stocks Based On Cash Flows by clicking here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com